Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
NCT ID: NCT05414461
Last Updated: 2022-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
97 participants
INTERVENTIONAL
2019-03-10
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
NCT05914389
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
NCT05148767
Establishment of Individualized Immunotherapy Strategy and Platform Based on Changes of Intestinal Microbiota
NCT05065515
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer
NCT03142282
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
NCT03008499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Combination treatment
PD-1 inhibitor-based combination treatment
Combinations
PD-1 inhibitor-based combinaiton treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combinations
PD-1 inhibitor-based combinaiton treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with identified genomic status
Exclusion Criteria
* patients who stopped treatment for any reason without identified response assessment.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Feng Ye
Chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CombiImmuno mCRC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.